Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Monoclonal antibody, composition taking same as active ingredient, and application of monoclonal antibody

A monoclonal antibody and composition technology, applied in the field of biology, achieves the effects of small injection volume, high degree of humanization, and small molecular weight

Inactive Publication Date: 2011-09-21
叶亚东
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no antibody that is exactly the same as the monoclonal antibody of the present invention

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monoclonal antibody, composition taking same as active ingredient, and application of monoclonal antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] The following examples of the present invention are presented for the purpose of illustration and not to limit the scope of the present invention.

[0018] Example 1. The production method of the monoclonal antibody of the present invention

[0019] Monoclonal antibody is produced by monoclonal method, which is a popular and practical process for preparing monoclonal antibody. Georges J.F. Kohler and Cesar Milstein first prepared monoclonal antibodies in the world in 1975. They won the Nobel Prize in Medicine and Physiology in 1984 because they proposed a method for preparing monoclonal antibodies.

[0020] Scientists have long known how to make antibodies. They inject antigens (such as viruses and tumor cells) into animals. B cells in the animal's immune system will release antibody molecules (molecules that specifically bind to antigens) in the blood. However, it is almost impossible to extract the required pure antibodies in batches from serum. Experiments usi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a monoclonal antibody, a composition taking same as an active ingredient, and application of the monoclonal antibody. The monoclonal antibody is a novel vascular endothelial growth factor A (VEGF-A) resistant human ScFv-Fc gene engineering antibody; the total molecular formula of the antibody is C2156H3272N561O681S12, and the molecular weight is 46KD; and the antibody is characterized in that: a full human antibody molecule specific to VEGF-A and capable of bonding with the VEGF-A in high affinity can be used for treating choroidal neovascularization (CNV) eye diseases. The monoclonal antibody can be widely applied and brings great social and economic benefits.

Description

technical field [0001] The present invention relates to the field of biology, specifically to a novel monoclonal antibody, more specifically to a novel anti-VEGF humanized ScFv-Fc genetically engineered antibody, and a pharmaceutical combination comprising the novel monoclonal antibody and the application of the novel monoclonal antibody in the treatment of CNV eye diseases. Background technique [0002] The following discussion of the background technology of the present invention is only provided to help readers understand the present invention, and does not admit that all the descriptions constitute the prior art of the present invention. [0003] Ocular neovascularization (CNV) is a common pathological change in many eye diseases, most commonly occurring in the cornea, iris, choroid and retina, including corneal neovascularization, age-related macular degeneration (AMD), diabetic retinopathy, premature infants Retinopathy (ROP), neovascular glaucoma, etc., and its accom...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/24A61K39/395A61P27/02A61P27/06C12N15/12
Inventor 叶亚东理查德·霍普
Owner 叶亚东
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com